Results 1 to 10 of about 11,882 (165)

Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP

Annals of Clinical and Translational Neurology, 2021
Objective Human T‐cell lymphotropic virus 1 (HTLV‐1)‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic, progressive myelopathy. A high proviral load (PVL) is one of the main risk factors for HAM/TSP.
Yoshimi Enose‐Akahata, Bridgette Jeanne Billioux, Shila Azodi, Jennifer Dwyer, Ashley Vellucci, Nyater Ngouth, Satoshi Nozuma, Raya Massoud, Irene Cortese, Joan Ohayon, Steven Jacobson   +10 more
doaj   +2 more sources

Undetectable proviral DNA and viral RNA levels after raltegravir administration in two cats with natural feline leukemia virus infection

Brazilian Journal of Veterinary Medicine, 2022
Feline leukemia virus (FeLV) infection was discovered over 50 years ago; however, the serious clinical changes associated with FeLV infection still have great importance in the diagnosis, prevention, and clinical management of symptomatic patients ...
Carla Regina Gomes Rodrigues Santos, Isabela Torres Ferreira, Renata Beranger, Julia Possebon Santi, Mariana Palha de Brito Jardim, Heloisa Justen Moreira de Souza   +5 more
doaj   +2 more sources

Influence of concurrent oral calcium carbonate supplementation on steady-state pharmacokinetics of once daily oral raltegravir in persons with HIV: a protocol for a prospective open-label non-randomised study in Canada [PDF]

BMJ Open
Introduction Raltegravir is a potent HIV-integrase strand transfer inhibitor (INSTI). Despite its strong activity against HIV-1 strains resistant to other antiretroviral drug classes, it is usually used in combination with other antiretroviral drugs due ...
Salmaan Kanji, Nancy Tremblay, D William Cameron, Bashour Yazji, Luana Leticia Teixeira Nunes Porto, Mary-Anne Doyle, Guijin Zhang   +6 more
doaj   +2 more sources

Raltegravir: first in class HIV integrase inhibitor

Therapeutics and Clinical Risk Management, 2008
Zelalem Temesgen1, Dawd S Siraj21Mayo Clinic, Rochester, MN, USA; 2East Carolina University Greenville, NC, USAAbstract: On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus ...
Zelalem Temesgen
exaly   +2 more sources

Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes.

Life Science, 2022
AIMS To assess the potential direct effects of the integrase strand-transfer inhibitors (INsTIs) dolutegravir, bictegravir, and raltegravir, drugs used as treatment for people living with human immunodeficiency virus (PLWH), on human adipose cells ...
P. Domingo, T. Quesada-López, J. Villarroya, M. Cairó, M. del Mar Gutierrez, M. Mateo, Isabel Mur, Noemí Corbacho, J. Domingo, F. Villarroya, M. Giralt   +10 more
semanticscholar   +1 more source

Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review

Journal of the International AIDS Society, 2022
Globally about 1.7 million children were living with HIV in 2020. Two integrase strand transfer inhibitors, dolutegravir and raltegravir, are increasingly used in children.
Claire L. Townsend, J. O'Rourke, Edith B. Milanzi, I. Collins, A. Judd, H. Castro, M. Vicari, J. Jesson, V. Leroy, F. Renaud, M. Penazzato   +10 more
semanticscholar   +1 more source

The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo

Cancers, 2021
Simple Summary Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide. Serrated adenocarcinoma (SAC) has been recently recognized by the WHO as a histological CRC with bad prognosis.
Begoña Alburquerque-González, Á. Bernabé-García, Manuel Bernabé-García, J. Ruiz-Sanz, Fernando F. López-Calderón, L. Gonnelli, L. Banci, J. Peña-García, I. Luque, F. J. Nicolás, María Luisa Cayuela-Fuentes, E. Luchinat, H. Pérez-Sánchez, S. Montoro-García, P. Conesa‐Zamora   +14 more
semanticscholar   +1 more source

Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.

Lancet. Infectious Diseases (Print), 2021
BACKGROUND In patients co-infected with HIV and tuberculosis, antiretroviral therapy options are limited due to drug-drug interactions with rifampicin. A previous phase 2 trial indicated that raltegravir 400 mg twice a day or efavirenz 600 mg once a day ...
N. de Castro, O. Marcy, C. Chazallon, E. Messou, S. Eholie, J. N’takpé, N. Bhatt, C. Khosa, Isabel Timana Massango, D. Laureillard, G. Chau, A. Domergue, V. Veloso, Rodrigo Escada, Sandra Wagner Cardoso, C. Delaugerre, X. Anglaret, J. Molina, B. Grinsztejn   +18 more
semanticscholar   +1 more source

Hepatic steatosis associated with exposure to elvitegravir and raltegravir.

Clinical Infectious Diseases, 2021
Moderate-to-severe hepatic steatosis in people living with HIV without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir and raltegravir.
D. Kirkegaard-Klitbo, M. T. Thomsen, M. Gelpi, F. Bendtsen, S. Nielsen, T. Benfield   +5 more
semanticscholar   +1 more source

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. [PDF]

PLoS ONE, 2009
Raltegravir is an HIV-1 integrase inhibitor currently used in treatment-experienced HIV-1-infected patients resistant to other drug classes. In order to assess its central nervous system penetration, we measured raltegravir concentrations in ...
Aylin Yilmaz, Magnus Gisslén, Serena Spudich, Evelyn Lee, Anura Jayewardene, Francesca Aweeka, Richard W Price   +6 more
doaj   +1 more source